Independent · Reader-Supported · Editorially Reviewed
§ Brand Review · GLP-1 Weight Loss

Hims Review

Publicly traded telehealth giant with weight-loss, ED, and hair-loss programs under one roof.

Last reviewed August 2026
7 studies cited
Fact-checked 12 August 2026Last updated 15 June 2026From $149 – $499/moEditor Score 4.5 / 5Trustpilot 2.9 · Poor

Reader-supported, we may earn a commission through links on this site. Rankings are editorially independent. Disclosure · Methodology

Quick Verdict

Publicly traded telehealth giant with weight-loss, ED, and hair-loss programs under one roof.

Who it's for: Hims is best suited to buyers who want a recognizable, publicly traded telehealth platform with broad category coverage and no insurance hassles. The proprietary MedMatch personalization layer matters most to people who plan to stay on the platform across multiple conditions.

Bottom line: A high-volume operator with one of the widest formularies in telehealth, useful for buyers who want a single login across categories. Look elsewhere if you want a boutique clinic relationship or specialist-grade depth in any one vertical.

Compare Hims on price, review history, and fit

Hims may be a strong fit. Before enrolling, compare its published details with three reviewed alternatives. Some links are compensated; editorial scores are independent.

See 6 alternatives vs Hims →
At-a-glance price and public review comparison
ProviderPublished priceTrustpilot
WellMedrFrom $49 – $129/mo4.6/5 (1,963)
TrimiFrom $99 – $125/moNot listed
SkinnyRxFrom $149 – $449/mo4.8/5 (5,335)
Pros
  • Both compounded and brand-name GLP-1 access
  • Single account spans weight loss, ED, and hair
  • Public-company transparency on financials
Cons
  • Insurance not accepted
  • Subscription auto-renewal model
  • State availability varies by program

Pros & Cons In Detail

Both compounded and brand-name GLP-1 access
Carrying both compounded and FDA-approved options gives Hims more flexibility if a patient needs to switch tracks for insurance, supply, or efficacy reasons mid-program.
Single account spans weight loss, ED, and hair
In practice this is one of the differentiators that pushes Hims's editor score above the category median.
Public-company transparency on financials
Clear, line-itemed pricing is increasingly rare in telehealth, and Hims discloses what you'll pay before you start a consult, not after card capture.
Insurance not accepted
It's a real trade-off worth knowing about before you commit, even if it isn't a deal-breaker on its own.
Subscription auto-renewal model
It's a real trade-off worth knowing about before you commit, even if it isn't a deal-breaker on its own.
State availability varies by program
Up-front lab work adds days to onboarding and a few dollars to the first month, although most clinicians would argue this is a feature rather than a bug.

Compare Before You Choose

Compare Hims on price, review history, and program fit.

A positive review is still a reason to compare before enrolling. Some links are compensated; editorial scores are independent.

See 6 alternatives vs Hims →
At-a-glance price and public review comparison
ProviderPublished priceTrustpilot
WellMedrFrom $49 – $129/mo4.6/5 (1,963)
TrimiFrom $99 – $125/moNot listed
SkinnyRxFrom $149 – $449/mo4.8/5 (5,335)

Hims Pricing

Telehealth ads often advertise a low headline price that's the clinic's program fee, not the medication. Here's how the two line items break down at Hims.

Program / Membership FeeIncluded in monthly plan
Medication Cost (From)From $149 – $499/mo
What This Means For You

Hims bundles provider visits, prescription, and shipping into a single monthly subscription. Compounded GLP-1 plans and brand-name medications are priced separately, with brand-name GLP-1s reflecting manufacturer list prices.

Who Hims Is For

Hims is best suited to buyers who want a recognizable, publicly traded telehealth platform with broad category coverage and no insurance hassles. The proprietary MedMatch personalization layer matters most to people who plan to stay on the platform across multiple conditions.

How Hims Markets Itself

Adults who want one publicly traded telehealth brand for weight loss, ED, and hair loss under a single account.

Signature Programs

  • ›Compounded GLP-1 weight loss
  • ›Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro
  • ›ED and hair-loss multi-category care

Medication Formulary

FDA-Approved Access
WegovyZepboundOzempicMounjaroViagraCialis
Full Formulary
compounded semaglutideoral semaglutidesildenafiltadalafilfinasterideminoxidil

The Bottom Line

A high-volume operator with one of the widest formularies in telehealth, useful for buyers who want a single login across categories. Look elsewhere if you want a boutique clinic relationship or specialist-grade depth in any one vertical.

With an editor score of 4.5 / 5 across cost, experience, and trust, Hims is one of the top-tier options in the glp-1 weight loss category we cover.

See how Hims compares in our full glp-1 weight loss rankings, or read the Best Telehealth GLP-1 Providers guide. Our methodology explains how we score each provider.

§ FAQ

Frequently Asked Questions

References
  1. Wilding et al., NEJM 2021 (STEP 1) · Semaglutide 2.4 mg produced 14.9% mean weight loss vs 2.4% placebo at 68 weeks in the STEP 1 trial.
  2. FDA Federal Register 2024 (Semaglutide shortage end) · FDA removed semaglutide from the drug shortage list in October 2024, ending the legal basis for compounding.
  3. Garvey et al., NEJM 2022 (STEP 5) · Two-year STEP 5 data confirmed sustained 15.2% weight loss with semaglutide 2.4 mg.
  4. Goldstein et al., NEJM 1998 (Sildenafil) · Pivotal NEJM trial establishing sildenafil efficacy: 69% of attempts successful vs 22% placebo.
  5. Jastreboff et al., NEJM 2022 (SURMOUNT-1 -- tirzepatide) · Tirzepatide 15 mg produced 20.9% mean weight loss vs 3.1% placebo at 72 weeks in SURMOUNT-1.
  6. FDA Prescribing Information: sildenafil citrate (Viagra) · FDA-approved prescribing information for sildenafil citrate tablets, including dosing, contraindications, and drug interactions.
  7. Kaufman & Dawber, JAAD 1998 (finasteride 1 mg for androgenetic alopecia) · Finasteride 1 mg daily reduced scalp DHT by approximately 60% and significantly increased hair count vs placebo in men with male-pattern hair loss.

RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.

§ Readers Also Compared

How Hims Stacks Up

Alternatives To Hims

Hims does not currently offer a direct online intake. The providers below offer similar programs and are accepting new patients.

Also Competes With

Hims also operates in Erectile Dysfunction, Hair Loss. Here are other providers in those spaces:

§ Continue Reading